Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Docetaxel + Glesatinib||Phase I||Actionable||In a Phase I trial, Glesatinib (MGCD265) and Taxotere (docetaxel) combination treatment resulted in partial response in 12% (4/34) and stable disease for 6 cycles or more in 18% (6/34) of patients with advanced solid tumors (J Clin Oncol 30, 2012 (suppl; abstr e13604)).||detail...|
|PubMed Id||Reference Title||Details|
|MGCD265, a multitargeted oral tyrosine kinase receptor inhibitor of Met and VEGFR, in combination with docetaxel.||Full reference...|